Compare Globus Medical Inc. Class A Common Stock (GMED) vs Iris Energy Limited (IREN) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

IREN trades at $34.80, showing no change in the last 24 hours. The stock faces bearish technical signals with recent earnings misses and a significant net loss margin of -99.38% in 2026 projections. Despite this, analyst consensus remains strongly bullish with an $81.00 price target, citing the company's pivot to AI infrastructure and major contracts with Microsoft and NVIDIA. Recent news highlights investor concerns over the $30 billion spending plan and execution risks amid the broader AI infrastructure boom.

The outlook for IREN hinges on successful execution of its AI pivot and capital-intensive expansion. While Wall Street sees substantial upside potential, risks include ballooning losses, high valuation multiples, and intense competition in the neocloud space. Investors should weigh the long-term growth narrative against near-term financial pressures and market volatility.